UA68441C2 - Purine derivatives, method for synthesis and pharmaceutical compositions - Google Patents

Purine derivatives, method for synthesis and pharmaceutical compositions Download PDF

Info

Publication number
UA68441C2
UA68441C2 UA2001128864A UA2001128864A UA68441C2 UA 68441 C2 UA68441 C2 UA 68441C2 UA 2001128864 A UA2001128864 A UA 2001128864A UA 2001128864 A UA2001128864 A UA 2001128864A UA 68441 C2 UA68441 C2 UA 68441C2
Authority
UA
Ukraine
Prior art keywords
radical
formula
radicals
cyclopentyl
phenyl
Prior art date
Application number
UA2001128864A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UA68441C2 publication Critical patent/UA68441C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA2001128864A 1999-05-21 2000-05-18 Purine derivatives, method for synthesis and pharmaceutical compositions UA68441C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
PCT/FR2000/001335 WO2000071543A1 (fr) 1999-05-21 2000-05-18 Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
UA68441C2 true UA68441C2 (en) 2004-08-16

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001128864A UA68441C2 (en) 1999-05-21 2000-05-18 Purine derivatives, method for synthesis and pharmaceutical compositions

Country Status (33)

Country Link
US (2) US7122669B1 (OSRAM)
EP (1) EP1183256B1 (OSRAM)
JP (1) JP2003500407A (OSRAM)
KR (1) KR100707895B1 (OSRAM)
CN (1) CN1298719C (OSRAM)
AP (1) AP1477A (OSRAM)
AR (1) AR035317A1 (OSRAM)
AT (1) ATE370951T1 (OSRAM)
AU (1) AU4764500A (OSRAM)
BR (1) BR0011282A (OSRAM)
CA (1) CA2374714A1 (OSRAM)
CZ (1) CZ20014163A3 (OSRAM)
DE (1) DE60036102T2 (OSRAM)
DK (1) DK1183256T3 (OSRAM)
DZ (1) DZ3166A1 (OSRAM)
EA (1) EA005072B1 (OSRAM)
ES (1) ES2290033T3 (OSRAM)
FR (1) FR2793794B1 (OSRAM)
HU (1) HUP0201649A3 (OSRAM)
IL (1) IL146441A0 (OSRAM)
MA (1) MA26791A1 (OSRAM)
MX (1) MXPA01011834A (OSRAM)
NO (1) NO20015659L (OSRAM)
NZ (1) NZ515556A (OSRAM)
PL (1) PL352293A1 (OSRAM)
PT (1) PT1183256E (OSRAM)
SK (1) SK16722001A3 (OSRAM)
TR (1) TR200103349T2 (OSRAM)
TW (1) TWI284130B (OSRAM)
UA (1) UA68441C2 (OSRAM)
WO (1) WO2000071543A1 (OSRAM)
YU (1) YU86601A (OSRAM)
ZA (1) ZA200109602B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
DE60138140D1 (de) * 2000-10-31 2009-05-07 Aventis Pharma Inc Acyl- und sulfonylderivative 6,9-disubstitutierter 2-(trans-1,4-diaminocyclohexyl)-purine und ihre verwendung als antiproliferative mittel
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
JP4664205B2 (ja) * 2002-10-15 2011-04-06 アイアールエム エルエルシー 骨形成を誘導する組成物および方法
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
EP1682150B1 (en) * 2003-11-10 2012-12-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2018064545A1 (en) * 2016-09-30 2018-04-05 Sri International Dual clk/cdk1 inhibitors for cancer treatment
CZ308029B6 (cs) 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
US20240247001A1 (en) 2022-12-16 2024-07-25 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
DE69231194T2 (de) * 1991-12-05 2001-02-15 Texas Instruments Inc., Dallas Verfahren zur Verbesserung eines Videosignals
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
US7091346B1 (en) * 1995-11-01 2006-08-15 Novartis Ag Purine derivatives and processes for their preparation
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
CA2297967A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
AP1477A (en) 2005-10-19
BR0011282A (pt) 2002-02-26
FR2793794A1 (fr) 2000-11-24
KR100707895B1 (ko) 2007-04-17
AU4764500A (en) 2000-12-12
MA26791A1 (fr) 2004-12-20
SK16722001A3 (sk) 2003-01-09
PL352293A1 (en) 2003-08-11
CA2374714A1 (fr) 2000-11-30
KR20010113975A (ko) 2001-12-28
EA005072B1 (ru) 2004-10-28
DK1183256T3 (da) 2007-12-03
EP1183256A1 (fr) 2002-03-06
DZ3166A1 (fr) 2000-11-30
TWI284130B (en) 2007-07-21
CZ20014163A3 (cs) 2002-10-16
WO2000071543A1 (fr) 2000-11-30
AP2001002355A0 (en) 2001-12-31
CN1361780A (zh) 2002-07-31
US7208598B2 (en) 2007-04-24
HUP0201649A2 (en) 2002-08-28
PT1183256E (pt) 2007-11-13
YU86601A (sh) 2005-07-19
ES2290033T3 (es) 2008-02-16
US7122669B1 (en) 2006-10-17
DE60036102T2 (de) 2008-05-15
MXPA01011834A (es) 2002-04-17
AR035317A1 (es) 2004-05-12
EA200101224A1 (ru) 2002-10-31
NZ515556A (en) 2003-08-29
US20050187228A1 (en) 2005-08-25
HUP0201649A3 (en) 2003-01-28
NO20015659D0 (no) 2001-11-20
ATE370951T1 (de) 2007-09-15
TR200103349T2 (tr) 2002-05-21
IL146441A0 (en) 2002-07-25
JP2003500407A (ja) 2003-01-07
EP1183256B1 (fr) 2007-08-22
FR2793794B1 (fr) 2001-07-27
DE60036102D1 (de) 2007-10-04
CN1298719C (zh) 2007-02-07
NO20015659L (no) 2002-01-18
ZA200109602B (en) 2003-01-29

Similar Documents

Publication Publication Date Title
UA68441C2 (en) Purine derivatives, method for synthesis and pharmaceutical compositions
CN101490052B (zh) 治疗性化合物及其在癌症中的用途
CN107980040B (zh) 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物
AU2023202058A1 (en) sGC Stimulators
CN116589459A (zh) 凋亡诱导剂
CN101248078A (zh) 抑制醛甾酮合酶和芳香酶的稠合咪唑并衍生物
NZ539095A (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
WO2010126960A1 (en) Pyrrolotriazine compounds
EP2523665A1 (en) Voltage-gated sodium channel blockers
MX2014004588A (es) Compuestos de (hetero) arilciclopropilamina como inhibidores de lsd1.
TW201524952A (zh) Kras g12c之共價抑制劑
UA76798C2 (uk) Заміщені 1,4-бензодіазепіни та їх використання для лікування раку, фармацевтична композиція (варіанти) на їх основі та спосіб лікування захворювань (варіанти)
AU2015272560B2 (en) Novel anticancer agent
NZ552183A (en) Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
WO2010136778A1 (en) Dibenzothiophene derivatives as dna- pk inhibitors
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
RS65161B1 (sr) Jedinjenja i kompozicije za indukciju hondrogeneze
JP2003525290A (ja) フラボンの新誘導体、それらの製造方法、それらの薬剤としての使用、製薬組成物及び新たな用途
WO2009130469A1 (en) Dna-pk inhibitors
JP2009519266A (ja) 炎症性の皮膚、眼および/または耳疾患を処置するためのジアリールウレア類
CN120225524A (zh) 嘧啶sGC刺激剂
EA046635B1 (ru) Соединение, содержащее бензольное кольцо, и его применение
HK1251549B (zh) 作为组蛋白去乙醯酶6抑制剂的1,3,4-恶二唑磺醯胺衍生物及含其的医药组合物
HK40017847A (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nsmase2) for the treatment of neurodegenerative diseases
HK40017847B (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nsmase2) for the treatment of neurodegenerative diseases